Kim So Young, Park Il Hwan, Byun Chun Sung, Choi Hyo Geun, Kwon Mi Jung, Kim Ji Hee, Kim Joo-Hee, Kim Chang Wan
Department of Anatomy and Cell Biology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Department of Cardiovascular and Thoracic Surgery, Yonsei University Wonju College of Medicine, Wonju 26426, Republic of Korea.
J Clin Med. 2024 May 27;13(11):3136. doi: 10.3390/jcm13113136.
: Previous studies have reported controversial results on the association between gout and the risk of cancer. This study aimed to investigate the relationship between gout and the incidence of head and neck cancer (HNC). : The data of participants who underwent health checkups in 2009 were analyzed using the National Health Insurance Database in South Korea. A total of 14,348 HNC patients and 57,392 control participants were analyzed for a prior history of gout. Overlap weighting was applied, and odds ratios (ORs) of gout for HNC patients were analyzed. The overlap-weighted model adjusted for demographic, socioeconomic, and lifestyle factors and comorbidities. HNC sites were classified as oral cavity cancer, oropharyngeal cancer, nasopharyngeal cancer, hypopharyngeal cancer, nasal cavity/sinus cancer, larynx cancer, or salivary gland cancer, and the ORs of gout were estimated for each site. : Overall, patients with HNC had 1.12-fold greater odds of having gout (95% confidence intervals [CIs] = 1.04-1.20). According to the site of HNC, oral cavity cancer, oropharynx cancer, and larynx cancer demonstrated high odds of having gout (OR = 1.25, 95% CI = 1.16-1.34 for oral cavity cancer; OR = 1.08, 95% CI = 1.01-1.15 for oropharynx cancer; and OR = 1.12, 95% CI = 1.06-1.20 for larynx cancer). On the other hand, nasal cavity/sinus cancer, nasopharynx cancer, and salivary gland cancer presented low odds of having gout (OR = 0.78, 95% CI = 0.72-0.84 for nasal cavity/sinus cancer; OR = 0.89, 95% CI = 0.83-0.96 for nasopharynx cancer; and OR = 0.88, 95% CI = 0.81-0.96 for salivary gland cancer). : A prior history of gout was associated with a high overall incidence of HNC. Oral cavity cancer, oropharynx cancer, and larynx cancer have a high incidence in gout patients. However, nasal cavity/sinus cancer, nasopharyngeal cancer, and salivary gland cancer have low incidences in gout patients. The impact of gout on HNC risk should be specifically considered according to the site of the HNC.
以往的研究报告了痛风与癌症风险之间存在争议性的结果。本研究旨在调查痛风与头颈癌（HNC）发病率之间的关系。
使用韩国国民健康保险数据库对2009年接受健康检查的参与者数据进行分析。共分析了14348名头颈癌患者和57392名对照参与者的痛风病史。应用重叠加权法，分析头颈癌患者痛风的比值比（OR）。重叠加权模型对人口统计学、社会经济、生活方式因素和合并症进行了调整。头颈癌部位分为口腔癌、口咽癌、鼻咽癌、下咽癌、鼻腔/鼻窦癌、喉癌或唾液腺癌，并估计每个部位痛风的OR。
总体而言，头颈癌患者患痛风的几率高1.12倍（95%置信区间[CI]=1.04-1.20）。根据头颈癌的部位，口腔癌、口咽癌和喉癌患痛风的几率较高（口腔癌的OR=1.25，95%CI=1.16-1.34；口咽癌的OR=1.08，95%CI=1.01-1.15；喉癌的OR=1.12，95%CI=1.06-1.20）。另一方面，鼻腔/鼻窦癌、鼻咽癌和唾液腺癌患痛风的几率较低（鼻腔/鼻窦癌的OR=0.78，95%CI=0.72-0.84；鼻咽癌的OR=0.89，95%CI=0.83-0.96；唾液腺癌的OR=0.88，95%CI=0.81-0.96）。
痛风病史与头颈癌的总体高发病率相关。痛风患者中口腔癌、口咽癌和喉癌的发病率较高。然而，痛风患者中鼻腔/鼻窦癌、鼻咽癌和唾液腺癌的发病率较低。应根据头颈癌的部位具体考虑痛风对其风险的影响。
